ScholarIQanswers from OpenAlex
Intercept Pharmaceuticals (United States)
InstitutionResearch output, impact & collaborations
Intercept Pharmaceuticals (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Intercept Pharmaceuticals (United States)?
ScholarIQrecord summary
Intercept Pharmaceuticals (United States) is a research organisation in New York, US. OpenAlex records 334 works and 69,505 citations for it.
How many works does Intercept Pharmaceuticals (United States) have?
ScholarIQindexed works
Intercept Pharmaceuticals (United States) has 334 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Intercept Pharmaceuticals (United States) have?
ScholarIQcitation count
Intercept Pharmaceuticals (United States) has 69,505 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Intercept Pharmaceuticals (United States)?
ScholarIQavg h-index
Intercept Pharmaceuticals (United States) has an average h-index of 95 in OpenAlex.
What is the ROR of Intercept Pharmaceuticals (United States)?
ScholarIQror
The ROR for Intercept Pharmaceuticals (United States) is on the source record.
What is the OpenAlex record for Intercept Pharmaceuticals (United States)?
ScholarIQopenalex
The OpenAlex for Intercept Pharmaceuticals (United States) is on the source record.
Who are the most-cited researchers behind Intercept Pharmaceuticals (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Intercept Pharmaceuticals (United States)?
ScholarIQmost cited works
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice
Eleni Beli, Yuanqing Yan, Leni Moldovan, Cristiano Pedrozo Vieira, Ruli Gao, Yaqian Duan, Ram Prasad, Ashay D. Bhatwadekar, Fletcher A. White, Steven D. Townsend, Luisa Chan, Caitlin N. Ryan, Daniel Morton, Emil G. Moldovan, Fang-I Chu, Gavin Y. Oudit, Hartmut Derendorf, Luciano Adorini, Xiaoxin X. Wang, Carmella Evans‐Molina, Raghavendra G. Mirmira, Michael E. Boulton, Mervin C. Yöder, Qiuhong Li, Moshe Levi, Julia V. Busik, Maria B. Grant
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Patrizia Mondello, Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain, Haopeng Yang, Shailbala Singh, Hsia‐Yuan Ying, Chi-Shuen Chu, Man Chun John, Eneda Toska, Stefan Alig, Matthew Durant, Elisa de Stanchina, Sreejoyee Ghosh, Anja Mottok, Loretta J. Nastoupil, Sattva S. Neelapu, Oliver Weigert, Giorgio Inghirami, José Baselga, Anas Younes, Cassian Yee, Ahmet Doǧan, David A. Scheinberg, Robert G. Roeder, Ari Melnick, Michael R. Green
How much of the research on Intercept Pharmaceuticals (United States) is open access?
ScholarIQopen access share
67%OPEN ACCESS